Cardiovascular Centre, OLV Aalst, Aalst, Belgium.
Cardiology Department, St. Antonius Hospital, Nieuwegein, the Netherlands.
JACC Clin Electrophysiol. 2022 Aug;8(8):1034-1039. doi: 10.1016/j.jacep.2022.05.017. Epub 2022 Jul 27.
Ultra-low temperature cryoablation (ULTC) is a novel ablation modality aiming to combine the effectiveness of surgical lesion delivery with percutaneous safety to improve outcomes in catheter ablations of atrial fibrillation, particularly in persistent AF (PsAF). In the Cryocure-2 study (NCT02839304) 78 patients (56.4% PsAF) received ULTC pulmonary vein isolation plus posterior wall ablation, and linear left and right atrial lesions as needed. The safety and acute success of ULTC appear consistent with current catheter ablation techniques and, together with Kaplan-Meier 85.9% 1-year freedom from AF observed in Cryocure-2 PsAF patients, warrant further evaluation in larger clinical trials, which are currently ongoing.
超低温冷冻消融（ULTC）是一种新型消融方式，旨在将手术性病灶传递的有效性与经皮安全性相结合，以改善心房颤动（AF）的导管消融结果，尤其是持续性 AF（PsAF）。在 Cryocure-2 研究（NCT02839304）中，78 例患者（56.4%为 PsAF）接受了 ULTC 肺静脉隔离加后壁消融，以及根据需要进行线性左房和右房消融。ULTC 的安全性和即刻成功率与当前的导管消融技术一致，加上在 Cryocure-2 PsAF 患者中观察到的 85.9%的 1 年无 AF 率，这使得 ULTC 有必要在更大的临床试验中进一步评估，目前正在进行中。
